Ticker Details
Prothena Corporation plc Ordinary Shares Prothena Corp PLC is a biotechnology company. It discovers and develops novel antibodies for the potential treatment of a broad range of diseases that involve protein misfolding or cell adhesion.
IPO Date:	December 21, 2012
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$569.55M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.85 | 2.86%
Avg Daily Range (30 D):	$0.21 | 2.27%
Avg Daily Range (90 D):	$0.21 | 2.21%

Institutional Daily Volume
Avg Daily Volume:	.38M
Avg Daily Volume (30 D):	.42M
Avg Daily Volume (90 D):	.42M

Trade Size
Avg Trade Size (Sh.):	76
Avg Trade Size (Sh.) (30 D):	43
Avg Trade Size (Sh.) (90 D):	51

Institutional Trades
Total Institutional Trades:	3,546
Avg Institutional Trade:	$1.85M
Avg Institutional Trade (30 D):	$.95M
Avg Institutional Trade (90 D):	$1.16M
Avg Institutional Trade Volume:	.06M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.16M
Avg Closing Trade (30 D):	$.91M
Avg Closing Trade (90 D):	$1.2M
Avg Closing Volume:	70.73K

News

Nov 12, 2025 @ 2:24 PM Novo Nordisk's $100 Million Coramitug Shows Promis... Source: Vandana Singh

Aug 29, 2025 @ 2:09 PM FDA Tightens Safety Guidelines For Biogen Leqembi ... Source: Vandana Singh

Feb 17, 2025 @ 11:10 PM Kuehn Law Encourages Investors of Prothena Corpora... Source: N/A

Feb 13, 2025 @ 6:00 PM Alpha-Synuclein Inhibitors Clinical Trial Pipeline... Source: Delveinsight

Dec 19, 2024 @ 4:31 PM Roche-Prothena Partnered Mid-Stage Parkinson's Tri... Source: Benzinga

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-4.53	$-.4	$-4.53
Diluted EPS	$-4.53	$-.4	$-4.53
Revenue	$9.68M	$.02M	$9.68M
Gross Profit
Net Income / Loss	$-244.09M	$-21.59M	$-244.09M
Operating Income / Loss	$-214.64M	$-24.2M	$-214.64M
Cost of Revenue
Net Cash Flow	$-163.86M	$-23.31M	$-163.86M
PE Ratio